In the past decade, intravitreal injections have transformed the way that we treat retinal disease, particularly vascular issues, with anti-VEGF medications. In the U.S., the most common ocular procedure is administration of an intravitreal injection, with many millions performed each year. This has evolved the way that we address conditions such as diabetic retinopathy, vascular occlusive disease and age-related macular degeneration. Sight has been protected and restored for countless patients, but an intravitreal injection is a procedure with a slight but real risk for complications.
These
Uncategorized